Generate Biomedicines, Inc. Proceeds from Issuance of Convertible Preferred Stock
Generate Biomedicines, Inc. (GENB) reported Proceeds from Issuance of Convertible Preferred Stock of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2026-08-06
- Generate Biomedicines, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2026-06-30 was $0.00.
- Generate Biomedicines, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Generate Biomedicines, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2025-06-30 was -$1.00K.
- Generate Biomedicines, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2025-03-31 was $21.97M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | |
| 2025-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $21.97M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $21.97M 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |